Can-Fite BioPharmaCANF
Market Cap: $12.9M
About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Employees: 5
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
38% more funds holding
Funds holding: 8 [Q1] → 11 (+3) [Q2]
37% more capital invested
Capital invested by funds: $1.18M [Q1] → $1.62M (+$435K) [Q2]
1.86% less ownership
Funds ownership: 1.9% [Q1] → 0.04% (-1.86%) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 331%upside $10 | Buy Maintained | 30 Aug 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 331%upside $10 | Buy Initiated | 17 Jul 2024 |